MDxHealth SA

MDxHealth SA announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, which fell short of expectations. The company expects to report Q3 2026 revenue of approximately $22.7 million, flat compared to the prior year. Due to unexpected sales force turnover, the company is suspending its full-year 2026 revenue guidance. MDxHealth plans to provide more details on corrective actions during its Q3 earnings call on November 12.

MDxHealth SA announced an amendment to its Articles of Association on August 13, 2026, to account for a capital increase involving 44,052,862 new shares. Following a Registered Direct Offering, the company's total outstanding ordinary shares will be 95,417,382. The company also referenced Securities Purchase Agreements related to the offering.

MDxHealth reported Q2 2026 financial results with revenue increasing 16% year-over-year to $27.2 million, driven by sequential growth and integration of the ExoDx business. However, the company experienced increased operating and net losses, and adjusted EBITDA turned negative, primarily due to higher operating expenses from the ExoDx acquisition. MDxHealth successfully completed the wind-down of its Resolve mdx business and secured $20 million in gross proceeds from a registered direct placement to institutional investors, strengthening its balance sheet and supporting future growth initiatives.

MDxHealth announced its second quarter 2026 financial results, reporting a 16% increase in revenue to $27.2 million. However, the company experienced a significant rise in operating loss to $5.1 million and net loss to $9.5 million, primarily due to increased operating expenses related to the ExoDx acquisition. The company also successfully completed the discontinuation of its Resolve mdx business and secured $20 million in gross proceeds from a registered direct placement, strengthening its balance sheet.

MDxHealth SA announced it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. The precision diagnostics company will host a conference call and webcast on the same day at 4:30pm ET / 22:30 CET to discuss the results and provide a corporate update. Dial-in details and a webcast link were provided for interested participants.

MDxHealth SA received an additional notice from Nasdaq on July 20, 2026, indicating non-compliance with the $35 million minimum Market Value of Listed Securities (MVLS) requirement. This follows an earlier notice regarding the minimum bid price. The company has been granted a 180-calendar day period, until January 19, 2027, to regain compliance by maintaining an MVLS of at least $35 million for 10 consecutive business days. The notice does not immediately affect the company's Nasdaq listing, and MDxHealth intends to address the deficiency.

MDxHealth SA announced it received an additional notification from Nasdaq regarding non-compliance with the minimum market value requirement of US$35 million. This follows a previous notification on July 2, 2026, for not meeting the $1.00 minimum bid price. The company has 180 calendar days, until January 19, 2027, to regain compliance by maintaining a market value above US$35 million for at least 10 consecutive business days. MDxHealth stated its business operations are not affected and it intends to cure the deficiency.

MDxHealth SA announced it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of US$1.00 per share. The company has been granted 180 calendar days, until December 28, 2026, to regain compliance by maintaining a closing bid price of at least US$1.00 for 10 consecutive business days. MDxHealth stated its business operations are unaffected and it may consider options like a reverse share split to address the deficiency.

MDxHealth reported Q1 2026 results, with revenue up 13% to $27.4 million and a net loss of $8.9 million. The company announced a strategic decision to discontinue its Resolve UTI offering and laboratory operations in Plano, Texas, citing an increasingly uncertain reimbursement landscape and a recent Medicare policy reversal. This proactive exit allows MDxHealth to focus on its core prostate cancer precision diagnostics business, for which it set updated 2026 revenue guidance of $110-115 million, representing 20-26% year-over-year growth. The company also initiated an AI-dedicated strategic initiative to enhance operations and clinical value, despite facing a $10.4 million Medicare recoupment decision for Resolve mdx claims.

MDxHealth reported its Q1 2026 financial results, with revenue increasing 13% to $27.4 million and net loss decreasing 4% to $(8.9) million. The company announced a strategic decision to discontinue its Resolve UTI offering and Plano, Texas laboratory operations due to an uncertain reimbursement landscape, aiming to refocus on its core prostate cancer precision diagnostics business. MDxHealth also updated its 2026 revenue guidance for the core cancer business to $110-115 million, representing 20-26% year-over-year growth, and disclosed a contested $10.4 million Medicare recoupment decision related to Resolve mdx claims.